高流量鼻导管较传统氧疗和无创正压通气能否降低成人急性呼吸衰竭患者气管插管率:系统评价与Meta分析
该系统评价与Meta分析检索了PubMed、Embase、Medline、Cochrane对照试验中心注册库和Web of Science,纳入比较高流量鼻导管(HFNC)与无创正压通气(NIPPV)及传统氧疗(COT)的对照研究,共纳入18项试验、3881例成人急性呼吸衰竭患者。主要终点为气管插管率,次要终点为ICU死亡率和ICU住院时间。结果示:与COT相比,HFNC与较低的气管插管率相关(z=2.55,P=.01);与NIPPV相比,气管插管率无显著差异(z=1.40,P=.16)。在ICU死亡率和ICU住院时间方面,HFNC未显示优于COT或NIPPV。
要点
- 成人急性呼吸衰竭患者中,与COT相比,HFNC与较低的气管插管率相关(z=2.55,P=.01)。
- 成人急性呼吸衰竭患者中,HFNC与NIPPV相比气管插管率无显著差异(z=1.40,P=.16)。
- HFNC在ICU死亡率和ICU住院时间方面未显示优于COT或NIPPV。
- HFNC与NIPPV比较时,ICU死亡率(I2=67%,χ2=12.21,P=.02)和气管插管率(I2=63%,χ2=13.51,P=.02)存在显著异质性。
适用人群与场景
- 成人急性呼吸衰竭患者,比较HFNC与NIPPV及COT的对照研究人群。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,共纳入18项试验、3881例成人急性呼吸衰竭患者。
- 主要终点:与COT相比,HFNC与较低的气管插管率相关(z=2.55,P=.01);与NIPPV相比,气管插管率无显著差异(z=1.40,P=.16)。
- 次要终点:HFNC在ICU死亡率和ICU住院时间方面未显示优于COT或NIPPV。
- 异质性:HFNC与NIPPV比较时,ICU死亡率(I2=67%,χ2=12.21,P=.02)和气管插管率(I2=63%,χ2=13.51,P=.02)存在显著异质性;其余结局指标未发现显著异质性。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,共纳入18项对照试验、3881例患者。
- 局限:HFNC与NIPPV比较时,ICU死亡率(I2=67%,χ2=12.21,P=.02)和气管插管率(I2=63%,χ2=13.51,P=.02)存在显著异质性。
对床旁实践的改变
- 在成人急性呼吸衰竭患者中,与COT相比,HFNC与较低的气管插管率相关;与NIPPV相比气管插管率无显著差异,ICU死亡率和ICU住院时间未见优势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effects of high-flow nasal cannula (HFNC) on adult patients with acute respiratory failure (ARF) are controversial. We aimed to further determine the effectiveness of HFNC in reducing the rate of endotracheal intubation in adult patients with ARF by comparison to noninvasive positive pressure ventilation (NIPPV) and conventional oxygen therapy (COT).
METHODS: The PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases, as well as the Information Sciences Institute Web of Science, were searched for all controlled studies that compared HFNC with NIPPV and COT in adult patients with ARF. The primary outcome was the rate of endotracheal intubation; the secondary outcomes were ICU mortality and length of ICU stay.
RESULTS: Eighteen trials with a total of 3,881 patients were pooled in our final studies. Except for ICU mortality (I2 = 67%, χ2 = 12.21, P = .02) and rate of endotracheal intubation (I2 = 63%, χ2 = 13.51, P = .02) between HFNC and NIPPV, no significant heterogeneity was found in outcome measures. Compared with COT, HFNC was associated with a lower rate of endotracheal intubation (z = 2.55, P = .01) while no significant difference was found in the comparison with NIPPV (z = 1.40, P = .16). As for ICU mortality and length of ICU stay, HFNC did not exhibit any advantage over either COT or NIPPV.
CONCLUSIONS: In patients with ARF, HFNC is a more reliable alternative than NIPPV to reduce the rate of endotracheal intubation than COT.
参考来源
- Ni YN, Luo J, Yu H, et al. Can High-flow Nasal Cannula Reduce the Rate of Endotracheal Intubation in Adult Patients With Acute Respiratory Failure Compared With Conventional Oxygen Therapy and Noninvasive Positive Pressure Ventilation?: A Systematic Review and Meta-analysis. Chest. 2017. PMID: 28089816. doi:10.1016/j.chest.2017.01.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。